Lepu Biopharma Co. Ltd. Class H (HK:2157)
:2157
Want to see HK:2157 full AI Analyst Report?
2157 Stock Chart & Stats
HK$4.98
-HK$0.04(-1.65%)
At close: 4:00 PM EST
HK$4.98
-HK$0.04(-1.65%)
Day’s Range― - ―
52-Week RangeHK$3.90 - HK$10.50
Previous CloseN/A
Volume4.02M
Average Volume (3M)13.90M
Market Cap
HK$8.25B
Enterprise ValueHK$7.15B
Total Cash (Recent Filing)HK$959.17M
Total Debt (Recent Filing)HK$1.06B
Price to Earnings (P/E)9.3
Beta0.87
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,804,439,800
10 Day Avg. Volume11,565,494
30 Day Avg. Volume13,902,953
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.65
Price to Sales (P/S)8.60
P/FCF Ratio-94.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.10Price Target Upside62.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$1.20B
Bulls Say, Bears Say
Bulls Say
2025 Revenue And Profit InflectionA meaningful revenue and profit inflection in 2025 demonstrates the company can scale commercial activity and convert R&D into recurring sales. If sustained, this reduces reliance on external financing, supports reinvestment in pipeline and commercialization, and underpins longer-term profitability.
Very High Gross Margins (~80%+)Consistently very high gross margins imply strong product-level economics and pricing power in core biologics/therapeutics. These margins support durable operating leverage as revenues scale, improving the company's ability to absorb R&D and SG&A while generating long-term cash profit per unit sold.
Improved Leverage And Positive ROE In 2025Improving debt-to-equity and a positive ROE indicate strengthened capital structure and that recent profits are generating shareholder returns. This enhances financial flexibility, supports better borrowing terms or partnerships, and reduces structural refinancing risk if profitability and equity base remain stable.
Bears Say
Negative Operating And Free Cash FlowDespite reported accounting profitability, persistent negative operating and free cash flow shows earnings have not converted into cash. This points to working-capital swings, investment intensity, or non-cash gains and elevates funding risk, increasing the odds of reliance on external financing over the medium term.
Meaningful Absolute Debt Load (~1.06B)A substantial absolute debt balance raises fixed obligations and reduces balance-sheet flexibility for a biotech with lumpy revenues. If cash conversion remains weak, interest and principal commitments heighten refinancing and covenant risk, pressuring resources for R&D and commercialization over the next several quarters.
Volatile Historical Profitability / Execution RiskA history of large prior losses followed by a one-year turnaround signals execution and consistency risk. Biotech revenue depends on approvals, launches, and partnerships; without repeatable commercial execution and regulatory progress, the 2025 profit may prove cyclical rather than structural.
Lepu Biopharma Co. Ltd. Class H News
2157 FAQ
What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$3.90 and its highest was HK$10.50 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$8.25B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Aug 26, 2026 which is in 97 days.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Lepu Biopharma Co. Ltd. Class H released its earnings results on Mar 25, 2026. The company reported HK$0.136 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.136.
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Undervalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.136 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.204%.
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lepu Biopharma Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$8.10 (62.65% Upside)
HK$8.10 (62.65% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.28%
12-Months-Change
Fundamentals
Return on Equity
24.17%
Trailing 12-Months
Asset Growth
43.87%
Trailing 12-Months
Company Description
Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.
2157 Stock 12 Month Forecast
Average Price Target
HK$8.10
▲(62.65% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---